BCCA Protocol Summary for Therapy for Advanced Prostate Cancer Using LHRH Antagonist Degarelix

Protocol Code: GUPLHRHA

Tumour Group: Genitourinary

Contact Physician: Dr. Kim Chi

ELIGIBILITY:
- advanced or metastatic prostate adenocarcinoma in patients who decline orchiectomy

TREATMENT OPTIONS:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BCCA Administration Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>degarelix</td>
<td>▪ Starting dose: 240 mg SC* (as two injections of 120 mg) on day 1, followed by maintenance dose: ▪ 80 mg SC* (as a single injection) every month, starting one month after starting dose.</td>
<td>SC</td>
</tr>
</tbody>
</table>

*Injections to be given in the abdominal region.

*To reduce incidence of injection site reactions: inject slowly; leave needle in place for 30 seconds after injection and then withdraw needle slowly

Duration: Depends on the indication for medical orchiectomy.

SIDE EFFECTS:
Hot flushing, impotence, gynecomastia, erythema and irritation of the injection site. Muscle weakness and weight gain, dizziness, pain, headache and paresthesias are common as well.

Call Dr. Kim Chi or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

Date activated: 1 July 2010
Date revised: 1 June 2014